Unipath launches unisex chlamydia test:
This article was originally published in Clinica
Unipath has introduced Clearview Chlamydia MF, a chlamydia test that is suitable for both male and female patients and can provide a result during a patient's visit. For male patients, a first-pass urine sample is diluted and centrifuged and chlamydial antigen extracted from the resulting pellet with a short heat extraction step. For female patients, an endocervical swab specimen is heat extracted. In either case, addition of the extract to the test unit gives results within 15 minutes. The company claims the test has high specificity and sensitivity.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.